Lv52
910 积分 2023-11-02 加入
Navigating the Evolving Landscape of EGFR -Mutated NSCLC
7小时前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
7小时前
已完结
Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis
1天前
已完结
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial
20天前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
1个月前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
1个月前
已完结
Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis
1个月前
已完结
Supplementary appendix 2
2个月前
已完结
A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells
2个月前
已完结
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
3个月前
已完结
皖公网安备34019202002308
